The glistening-free hydrophobic Vivinex™ IOL preloaded in the proven Vivinex™ iSertⓇ injector provides unprecedented clarity of vision.

Vivinex™ iSert™
UNPRECEDENTED CLARITY OF VISION.

The preloaded Vivinex™ IOL provides unprecedented clarity of vision in the proven
Vivinex™ iSert^® injector

Designed to provide outstanding optical quality, Vivinex™ offers unprecedented clarity of vision for patients suffering from cataract. Product quality, trust, dedication and attention to detail are deeply rooted in our Japanese heritage and with 1 million lenses sold worldwide, surgeons‘ trust in Vivinex™ is proven.

• Glistening-free hydrophobic acrylic IOL material ^1,3
• Proprietary aspheric optic design for improved image quality ⁵
• Active oxygen processing treatment and sharp optic edge to reduce PCO ¹

1 Clinical Evaluation of the HOYA VivinexTM IOL, HOYA data on file DoF-PHIV-101-SP2-12mIR-31082018 (2018).
3 Glistening-free per Miyata scale; study result of the David J Apple International Laboratory for Ocular Pathology, University Hospital Heidelberg. Report on file.
5 Pérez-Merino P, Marcos S. Effect of intraocular lens decentration on image quality tested in a custom model eye. J Cataract Refract Surg. 2018;44(7):889–896.

Specifications:

Available in Saudi Arabia, UAE, Oman, Qatar, Kuwait and Lebanon

Designed to provide outstanding optical quality, Vivinex™ offers clarity of vision for patients suffering from cataract. Vivinex™ is made from a novel glistening-free hydrophobic acrylic, using a proprietary manufacturing process that includes a unique, active oxygen posterior surface treatment [1,2,3]. This as well as its square edge design and one of the smoothest and most regular IOL surfaces has been shown to provide a low incidence of PCO in several studies [2,4,5,6,7,8,9,10].

multiSert™ provides unmatched control at the fingertips; it allows single-handed push and two-handed screw injection within one device. Has a uniquely designed adjustable insert shield for precise injector tip insertion depth management, allowing to insert the injector tip either directly into the capsular bag or through the incision wound tunnel. Moreover, multiSert™ provides outstandingly consistent and predictable IOL delivery [11].

Specifications

* The A-constant is presented as a starting point for the lens power calculation. When calculating the exact lens power, it is recommended that calculations be performed individually, based on the equipment used and operating surgeon’s own experience

** These optimized constants for the calculation of intraocular lens power published by IOLCon on their website: https://iolcon.org are calculated from 1,475 clinical results for Vivinex™ model XY1/XC1 as of September 24, 2021. These constants are based on actual surgical data and are provided by IOLCon as a starting point for individual constant optimizations. The information available on the website is based on data originating from other users and not by HOYA Surgical Optics (“HSO”). HSO therefore does not warrant the correctness, completeness and currentness of the contents on the said website.

Some of the products and/or specific features may not be registered in your country and thus may not be available there.

References

1. Glistening-free per Miyata scale; study result of the The David J Apple International Laboratory for Ocular Pathology, University Hospital Heidelberg. Report on file.

2. HOYA data on file. DoF-CTM-21-002, HOYA Medical Singapore Pte. Ltd, 2021

3. Pérez-Merino, P.; Marcos, S. (2018): Effect of intraocular lens decentration on image quality tested in a custom model eye. In: Journal of cataract and refractive surgery 44 (7), p. 889–896

4. Leydolt, C. et al. (2020): Posterior capsule opacification with two hydrophobic acrylic intraocular lenses: 3-year results of a randomized trial. In: American journal of ophthalmology 217 (9), p. 224-231

5. Giacinto, C. et al. (2019): Surface properties of commercially available hydrophobic acrylic intraocular lenses: Comparative study. In: Journal of cataract and refractive surgery 45 (9), p. 1330–1334.

6. Werner, L. et al. (2019): Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. In: Journal of cataract and refractive surgery 45 (10), p. 1490–1497

7. Matsushima, H. et al. (2006): Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. In: Journal of cataract and refractive surgery 32 (6), p. 1035–1040.

8. Farukhi, A. et al. (2015): Evaluation of uveal and capsule biocompatibility of a single-piece hydrophobic acrylic intraocular lens with ultraviolet-ozone treatment on the posterior surface. In: Journal of cataract and refractive surgery 41 (5), p. 1081–1087.

9. Eldred, J. et al. (2019): An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. In: Investigative ophthalmology & visual science 60(1), p. 113–122.

10. Nanavaty, M. et al. (2019): Edge profile of commercially available square-edged intraocular lenses: Part 2. In: Journal of cataract and refractive surgery 45 (6), p. 847–853

11. Usability and acceptability evaluation of the multiSert™ injector system, HOYA data on file DoF-SERT-102-MULT-03052018 (2018).

Designed to provide precise astigmatism correction and clarity of vision for patients with an astigmatic cornea. Vivinex™ Toric IOL offers outstanding optical quality and rotational stability, delivered by multiSert™, providing unmatched control at your fingertips [3,10,11].

Vivinex™ Toric, made of a glistening-free hydrophobic acrylic IOL material [1,2] with proprietary aspheric optic design for improved image quality [3], allows active oxygen processing treatment, a smooth surface and square optic edge to reduce PCO [2,4,5,6,7,8,9,10], as well as Median rotation 1.1° [range: 0.0°–5.0°] 100% of lenses (n=103) had ≤5° of rotation from their initial axis at end of surgery through all follow up visits at 1 hour, 1 week, 1 month and 6 months [11].

Specifications

* The A-constant is presented as a starting point for the lens power calculation. When calculating the exact lens power, it is recommended that calculations be performed individually, based on the equipment used and operating surgeon’s own experience.

** These optimized constants for the calculation of intraocular lens power published by IOLCon on their website: https://iolcon.org are calculated from 1,475 clinical results for Vivinex™ Model XY1/XC1 as of September  17, 2021. These constants are based on actual surgical data and are provided by IOLCon as a starting point for individual constant optimizations. The information available on the website is based on data originating from other users and not by HOYA Surgical Optics (“HSO”). HSO therefore does not warrant the correctness, completeness and currentness of the contents on the said website.

*** Based on an average pseudophakic human eye.

Some of the products and/or specific features may not be registered in your country and thus may not be available there.

References

1 Glistening-free  per  Miyata  scale;  study  result  of  the  David  J  Apple  International  Laboratory  for  Ocular  Pathology,  University  Hospital  Heidelberg.  Report  on  file.

2 HOYA  data  on  file.  DoF-CTM-21-002,  HOYA  Medical Singapore Pte. Ltd, 2021.

3 Pérez-Merino, P.; Marcos, S. (2018): Effect of intraocular lens decentration on image quality tested in a custom model eye. In: Journal of cataract and refractive surgery 44 (7), p. 889–896.

4 Leydolt, C. et al. (2020): Posterior capsule opacification with two hydrophobic acrylic intraocular lenses: 3-year results of a randomized trial. In: American journal of ophthalmology 217 (9), p. 224-231.

5 Giacinto, C. et al. (2019): Surface properties of commercially available hydrophobic acrylic intraocular lenses: Comparative study. In: Journal of cataract and refractive surgery 45 (9), p. 1330–1334.

6 Werner, L. et al. (2019): Evaluation of clarity characteristics in a new hydrophobic acrylic IOL in comparison to commercially available IOLs. In: Journal of cataract and refractive surgery 45 (10), p. 1490–1497.

7 Nanavaty, M. et al. (2019): Edge profile of commercially available square-edged intraocular lenses: Part 2. In: Journal of cataract and refractive surgery 45 (6), p. 847–853.

8 Matsushima, H. et al. (2006): Active oxygen processing for acrylic intraocular lenses to prevent posterior capsule opacification. In: Journal of cataract and refractive surgery 32 (6), p. 1035–1040.

9 Farukhi, A. et al. (2015): Evaluation of uveal and capsule biocompatibility of a single-piece hydrophobic acrylic intraocular lens with ultraviolet-ozone treatment on the posterior surface. In: Journal of cataract and refractive surgery 41 (5), p. 1081–1087.

10 Eldred, J. et al. (2019): An In Vitro Human Lens Capsular Bag Model Adopting a Graded Culture Regime to Assess Putative Impact of IOLs on PCO Formation. In: Investigative ophthalmology & visual science 60 (1), p. 113–122.

11 Schartmüller, D. et al. (2019): True rotational stability of a single-piece hydrophobic intraocular lens. In: The British journal of ophthalmology 103 (2), p. 186–190.

12 HOYA data on file. DoF-SERT-102-MULT-03052018, HOYA Medical Singapore Pte. Ltd, 2018 13 At IOL plane. 14 Based on an average pseudophakic human eye.

Vivinex Impress enhances the intermediate vision of monofocal patients.
It provides the same best-corrected mean distance acuity as a standard monofocal aspheric IOL.